促卵泡生成素受体（FSHR）拮抗剂与上皮性卵巢癌（EOC）
Follicle stimulating hormone receptor (FSHR) antagonist and epithelial ovarian cancer (EOC).
作者信息
Bose Chinmoy K
机构信息
Khidderpore Maternity Home, Kolkata, India.
出版信息
J Exp Ther Oncol. 2007;6(3):201-4.
INTRODUCTION
Follicle stimulating hormone receptor (FSHR), a G-protein coupled receptor present in granulosa cell of ovary is a unique transmembrane molecule pivotal in ovulation process. Its agonist and antagonists has remained the subject of interest to the reproductive biologists. It seems worthwhile to see what is new research on FSHR and whether they will be of any help in epithelial ovarian cancer.
METHODS
Pubmed and medline search was made from January 2006 to April 2006 to find out current development of FSHR antagonist research and role of FSHR in epithelial ovarian cancer
RESULTS
Effort to develop FSHR antagonist was mainly aimed at peptide antibody development. Breakthrough discovery of nonapeptide FSHR antagonist molecules, like suramin, compound 1 and compound 10 are noted. This is discussed in the context of nonsteroidal contraceptive for male and female. FSHR was found to have a distinguished role in precipitation of epithelial ovarian cancer. Hence, these antagonists might have a novel role to play in their treatment.
CONCLUSION
Author proposes the trial of these molecules as novel anticancer agents in epithelial ovarian cancer.
引言
促卵泡激素受体（FSHR）是一种存在于卵巢颗粒细胞中的G蛋白偶联受体，是排卵过程中关键的独特跨膜分子。其激动剂和拮抗剂一直是生殖生物学家感兴趣的课题。了解FSHR的最新研究以及它们是否对上皮性卵巢癌有帮助似乎很有价值。
方法
于2006年1月至2006年4月在PubMed和Medline上进行检索，以了解FSHR拮抗剂研究的当前进展以及FSHR在上皮性卵巢癌中的作用。
结果
开发FSHR拮抗剂的努力主要集中在肽抗体的研发上。值得注意的是，发现了非肽类FSHR拮抗剂分子的突破，如苏拉明、化合物1和化合物10。这在男女非甾体避孕药的背景下进行了讨论。发现FSHR在上皮性卵巢癌的发生中具有显著作用。因此，这些拮抗剂可能在其治疗中发挥新的作用。
结论
作者提议将这些分子作为上皮性卵巢癌的新型抗癌药物进行试验。
Zotero 插件